Back To Search Results

Neonatal Therapeutic Hypothermia

Editor: Palanikumar Balasundaram Updated: 2/25/2024 11:50:26 AM

Introduction

Hypoxic-ischemic encephalopathy (HIE) results from oxygen deprivation during the perinatal period and is a significant cause of infant mortality and neurodevelopmental deficits in neonates.[1] It is a significant health problem throughout the world. According to recent data, neonatal HIE incidence varies, with the most accepted rate of 1.5 per 1000 live births in developed countries; however, other studies show a significantly higher estimate.[2][3] The incidence in developing countries tends to be much higher, with estimates as high as 30 per 1000 births.[4][5][2][6]

The long-term morbidity and mortality for infants with HIE varies, with mortality rates ranging from 10% to 60% and neurodevelopmental disabilities in many survivors.[7][6][8] A systematic review concluded that therapeutic hypothermia is beneficial in neonates with HIE.[9] 

While it is accepted that parents of all term neonates with moderate or severe HIE should be offered therapeutic hypothermia, it is essential to note that there are several populations where therapeutic hypothermia is controversial or has shown little to no benefit.

Low- and Middle-Income Countries

A recent meta-analysis of 10 studies showed that therapeutic hypothermia in these settings showed little to no benefit in reducing death or severe disability. In addition, therapeutic hypothermia was associated with increased bleeding and thrombocytopenia.[10] However, this is controversial, and many experts advocate for continuing therapeutic hypothermia in these settings.[11][12]

Premature Babies Under 35 Weeks of Gestation

Retrospective analysis of preterm infants undergoing therapeutic hypothermia has resulted in concerning findings and the rate of adverse events.[13][14] A large randomized trial is underway to answer this question in this vulnerable population, and it is not currently the accepted standard of care to initiate therapeutic hypothermia in this population.

  • Therapeutic hypothermia for mild hypoxic-ischemic encephalopathy
    • Published data show babies with mild HIE are at significant risk of having lower cognitive scores than those without mild HIE.[15] However, it is unclear if therapeutic hypothermia benefits this population, and additional studies are needed to determine the long-term risks and benefits of therapeutic hypothermia in this group of babies.[16]
  • Late initiation of therapeutic hypothermia (6-24 hours after birth)
    • It is often impossible to begin therapeutic hypothermia within the accepted 6-hour time window studied in large randomized controlled trials. A recent randomized clinical trial showed that using Bayesian analysis, there was a 64% probability of benefit in death or disability.[17] However, changing current practices based on this analysis is controversial, and most centers have not implemented late cooling as a standard of care.[18]
  • Longer (120 hours vs 72 hours) or deeper (32 °C vs 33.5 °C)
    • In a randomized trial, longer or deeper therapeutic hypothermia did not show any benefit in outcomes at 18 months of age.[19]

Anatomy and Physiology

Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

Anatomy and Physiology

The mechanism of injury occurs in multiple steps, with an initial insult, followed by a latent (30 minutes-6 hours), secondary (6-12 hours to 3 days), and tertiary phase (months).[20]

  1. Initially, if the hypoxic insult is severe, there is an immediate decrease or cessation of glucose delivery, which causes ATP production to fail, resulting in primary neuronal death. For a more moderate injury, the brain will preferentially maintain circulation to critical areas such as the brainstem at the expense of the cerebral cortex and cerebral hemispheres, with the thalamus and basal ganglia most acutely affected.[20]   
  2. The latent phase begins within the first hour, assuming the oxygen supply is restored, and lasts 6 to 12 hours. In this phase, there is some recovery of the intracellular processes, as well as increased inflammation and further neuronal death due to apoptotic cascades.[20] This is the phase that is usually targeted with therapeutic hypothermia.                                                                                                                                                  
  3. The secondary phase begins after the latent phase and is characterized by free radical injury, mitochondrial failure, cell death, and possible clinical deterioration, often leading to seizures.[21][22].                                                   
  4. The tertiary phase follows and lasts months, involving remodeling and late cell death.[20][23]

The latent period between primary and secondary neuronal death is approximately 6 hours, and this is the window of opportunity to initiate therapeutic hypothermia, which is thought to help by reducing the cerebral metabolic rate, as well as other mechanisms such as reduced inflammation, reduced apoptosis as well as suppression of abnormal receptor activity.[24][25]

Indications

There are various inclusion criteria for the initiation of therapeutic hypothermia. The most commonly used inclusion criteria are based on the New England Journal of Medicine study, which showed the benefit of therapeutic hypothermia for infants with moderate to severe encephalopathy.[1]

To qualify for therapeutic hypothermia, the infant must meet all 3 of the criteria below (demographic, biochemical, and examination):

Demographic Criteria:

  • Gestational age 36 weeks or greater
  • Birth weight ≥1800 grams
  • The infant is within 6 hours of birth

Biochemical Criteria:

1. The infant's blood gas within the first hour of life (can be from cord blood or the baby's blood) has a pH of ≤7.0 or a base deficit of ≥16 mmol/L. If true, the infant meets the biochemical criteria and can proceed immediately with the examination criteria.

2. If, on the other hand, the infant's blood gas has a pH ≥7.0 but ≤7.15 or has a base deficit between 10 to15.9 mmol/L, or if there is no gas available within an hour, then the following additional criteria are required to move onto the examination criteria:                       

   A) Acute perinatal event (including but not limited to trauma, rupture, prolapse, etc) and   

   B) APGAR score of 5 or less at 10 minutes or assisted ventilation needed for at least 10 minutes after birth

It is important to note that the infant must meet either of the above main biochemical criteria to move on to the examination criteria.

Examination Criteria:

The infant must have moderate to severe encephalopathy on an exam, as defined by meeting the criteria of either moderate or severe encephalopathy in at least 3 of the 6 categories shown below (see Table. Examination Criteria).

Table. Examination Criteria

Category Moderate Encephalopathy Severe Encephalopathy
Level of Consciousness Lethargic Stupor or coma
Activity Decreased None
Posture Distal flexion, complete extension Decerebrate
Primitive Reflexes Weak suck or incomplete moro Absent suck or absent moro
Autonomic System

Constricted pupils, or

Bradycardia, or

Periodic breathing

Pupils deviated, dilated, or not reactive to light or

Variable heart rate, or

Apnea

Note: If the infant is confirmed to be experiencing seizures, the neonate automatically qualifies by examination criteria, and cooling should be initiated (assuming the demographic and biochemical criteria are also met). This is because seizures are a sign of HIE, and the rest of the neurological examination would not be accurate while the neonate is experiencing seizures.

If the infant meets the demographic, biochemical, and physical exam criteria, the infant qualifies for therapeutic hypothermia (barring any contraindications below). When an infant qualifies for therapeutic hypothermia, the risks and benefits should be discussed with parents, and cooling should be initiated immediately.

Contraindications

The exclusion criteria for therapeutic hypothermia are as follows: 

  1. Gestational age younger than 36 weeks 
  2. Birth weight < 1800 grams
  3. Older than 6 hours of age at the time of initiating therapeutic hypothermia (though some physicians will consider therapeutic hypothermia for up to 24 hours after birth)
  4. Major congenital abnormality
  5. Death appears inevitable
  6. Life-threatening coagulopathy with significant active bleeding may be an exclusion criterion. However, most infants have mild coagulopathy from the combined effects of asphyxia and cooling. Many infants have an increased rate of mild clinical bleeding and still benefit from therapeutic hypothermia.[26]
  7. Neurologically significant head trauma or skull fracture, causing major intracranial hemorrhage. Subgaleal bleeding is a relative contraindication for selective head cooling (SHC). Consider whole-body cooling (WBC) for these infants after initial stabilization.
  8. Imperforate anus is an exclusion criterion for SHC because rectal temperature recordings can not be obtained. Imperforate anus is not a contraindication for WBC with an esophageal probe.

Equipment

The required equipment for therapeutic hypothermia includes the following:

  • Cooling device 
  • A disposable esophageal probe or rectal temperature probe
  • Overhead warming bed with operative skin temperature probe
  • Cardiorespiratory monitor
  • Amplitude-integrated electroencephalography or electroencephalogram (EEG) should be available at the center (can start after cooling is initiated)
  • Gel pad for the head (for SHC)

Personnel

Required personnel for therapeutic hypothermia include the following:

  • Neonatologist or pediatrician with knowledge and experience managing critically ill neonates
  • Registered nurse
  • Pediatric neurologist (for reading of EEG and possible outpatient follow-up)

Preparation

Before initiating therapeutic hypothermia, the neonate should have vascular access. Central line access (umbilical arterial and double-lumen umbilical venous) is preferred. If umbilical access is difficult, insert a peripheral intravenous line and, if possible, a peripheral arterial line for continuous blood pressure monitoring. The infant must have a pulse oximeter and a cardiorespiratory monitor.

Assess the baseline clinical and neurological status and document this in the chart, including the criteria initially qualifying the neonate for therapeutic hypothermia. It is recommended that baseline labs be sent, including a complete blood count, coagulation profile, a complete metabolic panel, an arterial blood gas, and troponin. The labs should be repeated as needed throughout the cooling process, with the electrolytes repeated at least daily.

Technique or Treatment

Therapeutic hypothermia is administered by SHC or whole-body cooling WBC. 

  1. SHC requires a head cap that circulates cold water to decrease the core temperature of the neonate. The head and brain structures reach a cooler temperature than the body. The target temperature in SHC is 34 to 35 °C. Remove the cooling cap every 12 hours to look for an irritative scalp injury due to the cap. 
  2. WBC requires a special blanket that circulates water, which can be cooled or warmed. WBC achieves uniform cooling of the entire body. The target temperature in WBC is 33 to 34 °C.

Both cooling devices monitor the neonate's temperature with a probe and maintain the desired target temperature by altering the circulating water temperature. Therapeutic hypothermia should last 72 hours, followed by rewarming at 0.5 °C/hour.[27] Passive rewarming will continue for 4 hours in SHC or 6 hours in WBC.

Selective Head Cooling vs Whole-Body Cooling

  • WBC provides uniform cooling to all brain structures, including peripheral and central regions. SHC provides more cooling to the cortical region than to the central structures of the brain. 
  • WBC offers better or at least similar neuroprotection than SHC based on EEG and brain magnetic resonance imaging (MRI) findings of treated infants after cooling.[28]
  • WBC and SHC have similar safety and effectiveness. Also, side effects are similar in both methods. 
  • WBC is preferred to head cooling in most centers in the United States due to administration ease.
  • WBC also provides more accessible access to the scalp for EEG monitoring.

Passive Cooling 

If the neonatal unit is not equipped with a cooling facility, consider passive cooling for eligible neonates until they can be transferred to a cooling facility. The practical measures to achieve passive cooling are turning off the warmer or incubator, removing clothes, and not covering the baby with a blanket. The team should monitor the temperature efficiently at least every 15 to 30 minutes. Passive cooling can be an early adjunct to therapeutic hypothermia.[29]

Complications

Therapeutic hypothermia is usually well-tolerated, but short-term adverse effects are common.

  1. Cardiovascular complications  
    • Bradycardia- Heart rate decreases 15 beats per minute (bpm) per 1 °C change in temperature. At 33.5 °C, the heart rate is approximately 80 to 100 bpm. Neonates can tolerate significant bradycardia (60 to 80 bpm) if blood pressure is maintained adequately. If the heart rate is persistently below 60 bpm, obtain a full EKG.
    • Hypotension - Hypothermia decreases cardiac output and causes peripheral vasoconstriction, which leads to hypotension. Consider an echocardiogram to assess cardiac output. Maintain mean arterial pressure (MAP) >40 mmHg. Significant hypotension may necessitate a saline bolus, vasopressors, and steroids. 
    • Prolonged QT interval and ventricular arrhythmias
  2. Respiratory complications 
    • Impaired surfactant production
    • Hypothermia can also cause worsening of oxygenation due to induced pulmonary vasoconstriction and pulmonary hypertension. Pulmonary hypertension is usually reversible with rewarming.
    • Hypothermia shifts the oxyhemoglobin curve and can result in decreased oxygen delivery.
  3. Electrolyte imbalance
    • Hypokalemia 
    • Hyponatremia
    • Hypomagnesemia
    • Hypophosphatemia
  4. Coagulopathy, specifically platelet dysfunction
  5. Increased incidence of sepsis due to inhibition of a pro-inflammatory response
  6. Delayed gastric emptying causes intolerance of enteral feeds 
  7. Altered pharmacokinetics and pharmacodynamics of medications like sedatives and analgesics during hypothermia [30]

 During rewarming, complications can occur as follows:

  1. Seizures due to an increase in cerebral metabolic rate
  2. Apnea
  3. Higher risk of hypotension due to vasodilation of a constricted peripheral vascular bed [31]

Clinical Significance

The "Cool Cap" trial enrolled and randomly assigned 234 term neonates with moderate or severe HIE and abnormal amplitude-integrated EEG to either head cooling (n=116) or conventional management (n=118). The primary outcome measured was death or severe disability at 18 months. Death or disability occurred in 66% of conventional care and 55% of the cooled group (OR 0.61; 95% CI 0.34-1.09; P=0.1). Subgroup analysis revealed that head cooling did not significantly affect neonates with the worse changes in amplitude-integrated EEG (P=0.51) but was beneficial in infants with mild amplitude-integrated EEG changes (P=0.009). The study suggests that head cooling could safely improve survival without severe neurodevelopmental disability in neonates with less severe amplitude-integrated EEG changes.

The Total Body Hypothermia (TOBY) trial enrolled and randomly assigned 325 neonates with moderate or severe encephalopathy and abnormal aEEG to whole-body hypothermia or conventional care. The primary outcome measured was death or severe neurodevelopmental disability at 18 months. Death or severe disability occurred in 53% of conventional care cases and 45% of the cooling group (RR 0.86 [0.68 - 1.07]; P=0.17). Infants undergoing hypothermia had an increased survival rate without neurologic deficit (= 0.003). The TOBY trial suggested that induction of therapeutic hypothermia in infants with perinatal asphyxia did not significantly reduce the combined mortality rate or severe disability but improved neurologic outcomes among survivors.[32]

The NICHD Neonatal Research Network (NRN) trial randomly assigned term infants (n=208) with moderate or severe encephalopathy to WBC to an esophageal temperature of 33.5 °C for 72 hours or usual care. The primary outcome measured was death or disability at 18 months. Whole-body hypothermia decreased mortality or disability in infants with moderate or severe HIE compared to conservative care (RR 0.72; CI 0.54-0.95; P=0.01).[1]

The Infant Cooling Evaluation (ICE) trial (n=221) is the most recent randomized controlled trial published. The mortality or significant disability at 2 years of age occurred in 51% of the cooling group and 66% of the control groups (RR 0.77; CI 0.62 to 0.98). The mortality rate was significantly low, and survival free of disability was higher in the cooling group than in the control group.[33]

A systematic review of 11 randomized controlled trials (n=1505) on cooling for newborns with HIE suggested that therapeutic hypothermia benefits neonates with moderate to severe HIE. Therapeutic hypothermia decreased mortality without increasing significant disability among survivors. The benefits of survival and neurodevelopmental outcomes outweighed the short-term adverse effects.[9]

Enhancing Healthcare Team Outcomes

Effective use of therapeutic hypothermia in neonates demands an interprofessional team of healthcare professionals working in a coordinated manner. Physicians, advanced care practitioners, nurses, pharmacists, and other healthcare professionals have crucial and specific responsibilities within the neonatal therapeutic hypothermia team. Duties range from accurate patient assessment to timely intervention and ongoing monitoring.

Therapeutic hypothermia involves critical time-sensitive management. A therapeutic window of 6 hours from birth is crucial. The healthcare team should be aware of therapeutic hypothermia's exclusion criteria. If an eligible neonate is born in a setting without a cooling facility, the referring facility may initiate passive cooling. At the same time, the transport team must transport the neonate as soon as possible to a facility with cooling capabilities.  

Developing a cohesive strategy involves collaborative goal-setting and planning. This includes establishing standardized protocols for therapeutic hypothermia, anticipating potential challenges, and strategizing ways to enhance the efficiency of care delivery. Though therapeutic hypothermia is well-tolerated, short-term adverse effects are common with therapeutic hypothermia. The neonate needs continuous monitoring to assess for complications. 

Each healthcare professional must possess specialized skills relevant to their role, including proficiency in assessing neonatal conditions, implementing therapeutic hypothermia protocols, and managing potential complications. Continuous training and updates on best practices are essential to maintain these skills.

Effective communication is pivotal for successful teamwork. Regular, clear, and respectful communication among interprofessional team members ensures seamless coordination of care, timely response to changing conditions, and shared decision-making. Care coordination involves scheduling interventions, sharing patient information, and aligning treatment plans, ensuring a unified and patient-centered approach. A collaborative and multidisciplinary healthcare team can improve outcomes, prioritize patient safety, and elevate overall team performance in neonatal therapeutic hypothermia.

Nursing, Allied Health, and Interprofessional Team Interventions

The interprofessional team needs to be involved in the care of these neonates. The neonate must be monitored at all times by the bedside nurse to ensure hemodynamic stability and the presence of any complications.

Nursing, Allied Health, and Interprofessional Team Monitoring

Neonatal therapeutic hypothermia is associated with several physiologic derangements. Frequent monitoring is crucial for the early detection and management of complications.

Cardiovascular:                                     

  • Monitor blood pressure, heart rate, and perfusion status
  • Monitor continuous mean arterial pressure (MAP) through arterial lines
  • Obtain EKG if there is significant bradycardia 
  • Consider an echocardiogram if persistent hypotension occurs                                                                 

Respiratory:

  • Initially, frequent blood gas monitoring (q 4 hrs) may be necessary. The partial pressure of gases depends on the temperature. It is essential to adjust the blood gas machine for the "actual" core temperature before running the sample.
  • Maintain arterial blood gas pCO2 within the normal range at 38 to 45 mmHg. PaO2 should be >60 and <100 mmHg.                                                                                                                                    

Neurological:

  • Infants on therapeutic hypothermia need frequent neurologic assessment. Check pupils and level of consciousness, and look for signs of seizures or raised intracranial pressure.
  • Neonates may need to receive morphine for cold stress. However, some data suggest that this may prolong the hospital course.[34] 
  • Watch for oversedation due to possible accumulation because of altered pharmacokinetics, especially if the neonate is on phenobarbital, as this might mask neurological examination.
  • Commence an EEG or complete EEG monitoring if possible, at least during the initial cooling and rewarming periods, as seizures are common in this group.
  • Consider brain MRI at 4 to 10 days of life after the neonate has completed therapeutic hypothermia when any diffusion-weighted imaging abnormalities are still apparent.[35]
  • Pediatric neurology should be consulted to help guide long-term prognosis and follow-up and to help manage seizures should they occur.                                                                                              

Fluid and Electrolytes:

  • Even though many centers keep infants nil-per-os (NPO) during therapeutic hypothermia, recent studies suggest feeding is not harmful to these infants and should be implemented as tolerated.[36][37]
  • Start the total fluid rate at 50 to 60 mL/kg/day and adjust based on the baby's clinical status.[38]
  • Maintain glucose and electrolytes within normal limits.                           
  • SIADH (syndrome of inappropriate anti-diuretic hormone) is also common after perinatal asphyxia. Sodium levels could fall due to increased renal loss in hypothermia.                                                                     

Blood work: 

  • Arterial blood gas, electrolytes, renal function tests, liver function tests, coagulation profiles, and glucose need to be performed when initiating therapeutic hypothermia and as needed after that.

Skincare: 

  • Assessing the integrity of the skin every 6 hours is an integral part of therapeutic hypothermia.

Strict Infection Control Measures: 

  • Hypothermia can cause immune dysfunction; thus, standard precautions should be observed.

References


[1]

Shankaran S, Laptook AR, Ehrenkranz RA, Tyson JE, McDonald SA, Donovan EF, Fanaroff AA, Poole WK, Wright LL, Higgins RD, Finer NN, Carlo WA, Duara S, Oh W, Cotten CM, Stevenson DK, Stoll BJ, Lemons JA, Guillet R, Jobe AH, National Institute of Child Health and Human Development Neonatal Research Network. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. The New England journal of medicine. 2005 Oct 13:353(15):1574-84     [PubMed PMID: 16221780]

Level 1 (high-level) evidence

[2]

Kurinczuk JJ, White-Koning M, Badawi N. Epidemiology of neonatal encephalopathy and hypoxic-ischaemic encephalopathy. Early human development. 2010 Jun:86(6):329-38. doi: 10.1016/j.earlhumdev.2010.05.010. Epub 2010 Jun 16     [PubMed PMID: 20554402]


[3]

Palsdottir K, Dagbjartsson A, Thorkelsson T, Hardardottir H. [Birth asphyxia and hypoxic ischemic encephalopathy, incidence and obstetric risk factors]. Laeknabladid. 2007 Sep:93(9):595-601     [PubMed PMID: 17823499]

Level 2 (mid-level) evidence

[4]

Itoo BA, Al-Hawsawi ZM, Khan AH. Hypoxic ischemic encephalopathy. Incidence and risk factors in North Western Saudi Arabia. Saudi medical journal. 2003 Feb:24(2):147-53     [PubMed PMID: 12682677]

Level 2 (mid-level) evidence

[5]

Greco P, Nencini G, Piva I, Scioscia M, Volta CA, Spadaro S, Neri M, Bonaccorsi G, Greco F, Cocco I, Sorrentino F, D'Antonio F, Nappi L. Pathophysiology of hypoxic-ischemic encephalopathy: a review of the past and a view on the future. Acta neurologica Belgica. 2020 Apr:120(2):277-288. doi: 10.1007/s13760-020-01308-3. Epub 2020 Feb 28     [PubMed PMID: 32112349]


[6]

Namusoke H, Nannyonga MM, Ssebunya R, Nakibuuka VK, Mworozi E. Incidence and short term outcomes of neonates with hypoxic ischemic encephalopathy in a Peri Urban teaching hospital, Uganda: a prospective cohort study. Maternal health, neonatology and perinatology. 2018:4():6. doi: 10.1186/s40748-018-0074-4. Epub 2018 Mar 7     [PubMed PMID: 29556412]


[7]

Tsuda K, Shibasaki J, Isayama T, Takeuchi A, Mukai T, Sugiyama Y, Ioroi T, Takahashi A, Yutaka N, Iwata S, Nabetani M, Iwata O. Three-year outcome following neonatal encephalopathy in a high-survival cohort. Scientific reports. 2022 May 13:12(1):7945. doi: 10.1038/s41598-022-12091-x. Epub 2022 May 13     [PubMed PMID: 35562399]


[8]

Ezenwa BN, Olorunfemi G, Fajolu I, Adeniyi T, Oleolo-Ayodeji K, Kene-Udemezue B, Olamijulo JA, Ezeaka C. Trends and predictors of in-hospital mortality among babies with hypoxic ischaemic encephalopathy at a tertiary hospital in Nigeria: A retrospective cohort study. PloS one. 2021:16(4):e0250633. doi: 10.1371/journal.pone.0250633. Epub 2021 Apr 26     [PubMed PMID: 33901237]

Level 2 (mid-level) evidence

[9]

Jacobs SE, Berg M, Hunt R, Tarnow-Mordi WO, Inder TE, Davis PG. Cooling for newborns with hypoxic ischaemic encephalopathy. The Cochrane database of systematic reviews. 2013 Jan 31:2013(1):CD003311. doi: 10.1002/14651858.CD003311.pub3. Epub 2013 Jan 31     [PubMed PMID: 23440789]

Level 1 (high-level) evidence

[10]

Bellos I, Devi U, Pandita A. Therapeutic Hypothermia for Neonatal Encephalopathy in Low- and Middle-Income Countries: A Meta-Analysis. Neonatology. 2022:119(3):300-310. doi: 10.1159/000522317. Epub 2022 Mar 25     [PubMed PMID: 35340015]

Level 1 (high-level) evidence

[11]

Ballot DE, Ramdin TD, Bandini RM, Nakwa F, Velaphi S, Coetzee M, Masemola K, Kali GJD, Horn AR, Pillay S, Van Rensburg J, Pepper MS. Therapeutic hypothermia for neonatal hypoxic ischaemic encephalopathy should not be discontinued in low- and middle-income countries. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde. 2021 Dec 2:111(12):1168-1169. doi: 10.7196/SAMJ.2021.v111i12.16180. Epub 2021 Dec 2     [PubMed PMID: 34949301]


[12]

Mathew JL, Kaur N, Dsouza JM. Therapeutic Hypothermia for Neonatal Encephalopathy in Low-Resource Settings: Methodological Inaccuracies and Inconsistencies in the Latest Systematic Review. Neonatology. 2023:120(2):268-269. doi: 10.1159/000526596. Epub 2022 Nov 10     [PubMed PMID: 36366813]

Level 1 (high-level) evidence

[13]

Herrera TI, Edwards L, Malcolm WF, Smith PB, Fisher KA, Pizoli C, Gustafson KE, Goldstein RF, Cotten CM, Goldberg RN, Bidegain M. Outcomes of preterm infants treated with hypothermia for hypoxic-ischemic encephalopathy. Early human development. 2018 Oct:125():1-7. doi: 10.1016/j.earlhumdev.2018.08.003. Epub 2018 Aug 23     [PubMed PMID: 30144709]


[14]

Rao R, Trivedi S, Vesoulis Z, Liao SM, Smyser CD, Mathur AM. Safety and Short-Term Outcomes of Therapeutic Hypothermia in Preterm Neonates 34-35 Weeks Gestational Age with Hypoxic-Ischemic Encephalopathy. The Journal of pediatrics. 2017 Apr:183():37-42. doi: 10.1016/j.jpeds.2016.11.019. Epub 2016 Dec 13     [PubMed PMID: 27979578]


[15]

Finder M, Boylan GB, Twomey D, Ahearne C, Murray DM, Hallberg B. Two-Year Neurodevelopmental Outcomes After Mild Hypoxic Ischemic Encephalopathy in the Era of Therapeutic Hypothermia. JAMA pediatrics. 2020 Jan 1:174(1):48-55. doi: 10.1001/jamapediatrics.2019.4011. Epub     [PubMed PMID: 31710357]


[16]

Berube MW, Puia-Dumitrescu M, McAdams RM. Does mild hypoxic ischemic encephalopathy adversely affect neurodevelopmental outcome? Journal of perinatology : official journal of the California Perinatal Association. 2021 Apr:41(4):901-904. doi: 10.1038/s41372-021-01026-5. Epub 2021 Mar 13     [PubMed PMID: 33714978]


[17]

Laptook AR, Shankaran S, Tyson JE, Munoz B, Bell EF, Goldberg RN, Parikh NA, Ambalavanan N, Pedroza C, Pappas A, Das A, Chaudhary AS, Ehrenkranz RA, Hensman AM, Van Meurs KP, Chalak LF, Khan AM, Hamrick SEG, Sokol GM, Walsh MC, Poindexter BB, Faix RG, Watterberg KL, Frantz ID 3rd, Guillet R, Devaskar U, Truog WE, Chock VY, Wyckoff MH, McGowan EC, Carlton DP, Harmon HM, Brumbaugh JE, Cotten CM, Sánchez PJ, Hibbs AM, Higgins RD, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Effect of Therapeutic Hypothermia Initiated After 6 Hours of Age on Death or Disability Among Newborns With Hypoxic-Ischemic Encephalopathy: A Randomized Clinical Trial. JAMA. 2017 Oct 24:318(16):1550-1560. doi: 10.1001/jama.2017.14972. Epub     [PubMed PMID: 29067428]

Level 1 (high-level) evidence

[18]

Walløe L, Hjort NL, Thoresen M. Major concerns about late hypothermia study. Acta paediatrica (Oslo, Norway : 1992). 2019 Apr:108(4):588-589. doi: 10.1111/apa.14640. Epub 2018 Nov 28     [PubMed PMID: 30417430]


[19]

Shankaran S, Laptook AR, Pappas A, McDonald SA, Das A, Tyson JE, Poindexter BB, Schibler K, Bell EF, Heyne RJ, Pedroza C, Bara R, Van Meurs KP, Huitema CMP, Grisby C, Devaskar U, Ehrenkranz RA, Harmon HM, Chalak LF, DeMauro SB, Garg M, Hartley-McAndrew ME, Khan AM, Walsh MC, Ambalavanan N, Brumbaugh JE, Watterberg KL, Shepherd EG, Hamrick SEG, Barks J, Cotten CM, Kilbride HW, Higgins RD, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Effect of Depth and Duration of Cooling on Death or Disability at Age 18 Months Among Neonates With Hypoxic-Ischemic Encephalopathy: A Randomized Clinical Trial. JAMA. 2017 Jul 4:318(1):57-67. doi: 10.1001/jama.2017.7218. Epub     [PubMed PMID: 28672318]

Level 1 (high-level) evidence

[20]

Douglas-Escobar M, Weiss MD. Hypoxic-ischemic encephalopathy: a review for the clinician. JAMA pediatrics. 2015 Apr:169(4):397-403. doi: 10.1001/jamapediatrics.2014.3269. Epub     [PubMed PMID: 25685948]


[21]

Bennet L, Roelfsema V, Pathipati P, Quaedackers JS, Gunn AJ. Relationship between evolving epileptiform activity and delayed loss of mitochondrial activity after asphyxia measured by near-infrared spectroscopy in preterm fetal sheep. The Journal of physiology. 2006 Apr 1:572(Pt 1):141-54     [PubMed PMID: 16484298]

Level 3 (low-level) evidence

[22]

Gunn AJ, Gunn TR, de Haan HH, Williams CE, Gluckman PD. Dramatic neuronal rescue with prolonged selective head cooling after ischemia in fetal lambs. The Journal of clinical investigation. 1997 Jan 15:99(2):248-56     [PubMed PMID: 9005993]

Level 3 (low-level) evidence

[23]

Bennet L, Tan S, Van den Heuij L, Derrick M, Groenendaal F, van Bel F, Juul S, Back SA, Northington F, Robertson NJ, Mallard C, Gunn AJ. Cell therapy for neonatal hypoxia-ischemia and cerebral palsy. Annals of neurology. 2012 May:71(5):589-600. doi: 10.1002/ana.22670. Epub     [PubMed PMID: 22522476]

Level 3 (low-level) evidence

[24]

Chiang MC, Lien R, Chu SM, Yang PH, Lin JJ, Hsu JF, Fu RH, Lin KL. Serum Lactate, Brain Magnetic Resonance Imaging and Outcome of Neonatal Hypoxic Ischemic Encephalopathy after Therapeutic Hypothermia. Pediatrics and neonatology. 2016 Feb:57(1):35-40. doi: 10.1016/j.pedneo.2015.04.008. Epub 2015 May 27     [PubMed PMID: 26141483]


[25]

Drury PP, Bennet L, Gunn AJ. Mechanisms of hypothermic neuroprotection. Seminars in fetal & neonatal medicine. 2010 Oct:15(5):287-92. doi: 10.1016/j.siny.2010.05.005. Epub 2010 Jun 19     [PubMed PMID: 20646974]


[26]

Wang CH, Chen NC, Tsai MS, Yu PH, Wang AY, Chang WT, Huang CH, Chen WJ. Therapeutic Hypothermia and the Risk of Hemorrhage: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Medicine. 2015 Nov:94(47):e2152. doi: 10.1097/MD.0000000000002152. Epub     [PubMed PMID: 26632746]

Level 1 (high-level) evidence

[27]

Tagin MA, Woolcott CG, Vincer MJ, Whyte RK, Stinson DA. Hypothermia for neonatal hypoxic ischemic encephalopathy: an updated systematic review and meta-analysis. Archives of pediatrics & adolescent medicine. 2012 Jun 1:166(6):558-66. doi: 10.1001/archpediatrics.2011.1772. Epub     [PubMed PMID: 22312166]

Level 1 (high-level) evidence

[28]

Goenka A, Yozawitz E, Gomes WA, Nafday SM. Selective Head versus Whole Body Cooling Treatment of Hypoxic-Ischemic Encephalopathy: Comparison of Electroencephalogram and Magnetic Resonance Imaging Findings. American journal of perinatology. 2020 Oct:37(12):1264-1270. doi: 10.1055/s-0039-1693466. Epub 2019 Jul 25     [PubMed PMID: 31344712]


[29]

Anderson ME, Longhofer TA, Phillips W, McRay DE. Passive cooling to initiate hypothermia for transported encephalopathic newborns. Journal of perinatology : official journal of the California Perinatal Association. 2007 Sep:27(9):592-3     [PubMed PMID: 17724456]

Level 3 (low-level) evidence

[30]

Zanelli S, Buck M, Fairchild K. Physiologic and pharmacologic considerations for hypothermia therapy in neonates. Journal of perinatology : official journal of the California Perinatal Association. 2011 Jun:31(6):377-86. doi: 10.1038/jp.2010.146. Epub 2010 Dec 23     [PubMed PMID: 21183927]

Level 3 (low-level) evidence

[31]

Shankaran S. Therapeutic hypothermia for neonatal encephalopathy. Current treatment options in neurology. 2012 Dec:14(6):608-19. doi: 10.1007/s11940-012-0200-y. Epub     [PubMed PMID: 23007949]


[32]

Azzopardi DV, Strohm B, Edwards AD, Dyet L, Halliday HL, Juszczak E, Kapellou O, Levene M, Marlow N, Porter E, Thoresen M, Whitelaw A, Brocklehurst P, TOBY Study Group. Moderate hypothermia to treat perinatal asphyxial encephalopathy. The New England journal of medicine. 2009 Oct 1:361(14):1349-58. doi: 10.1056/NEJMoa0900854. Epub     [PubMed PMID: 19797281]

Level 1 (high-level) evidence

[33]

Jacobs SE, Morley CJ, Inder TE, Stewart MJ, Smith KR, McNamara PJ, Wright IM, Kirpalani HM, Darlow BA, Doyle LW, Infant Cooling Evaluation Collaboration. Whole-body hypothermia for term and near-term newborns with hypoxic-ischemic encephalopathy: a randomized controlled trial. Archives of pediatrics & adolescent medicine. 2011 Aug:165(8):692-700. doi: 10.1001/archpediatrics.2011.43. Epub 2011 Apr 4     [PubMed PMID: 21464374]

Level 1 (high-level) evidence

[34]

Liow N, Montaldo P, Lally PJ, Teiserskas J, Bassett P, Oliveira V, Mendoza J, Slater R, Shankaran S, Thayyil S. Preemptive Morphine During Therapeutic Hypothermia After Neonatal Encephalopathy: A Secondary Analysis. Therapeutic hypothermia and temperature management. 2020 Mar:10(1):45-52. doi: 10.1089/ther.2018.0052. Epub 2019 Feb 26     [PubMed PMID: 30807267]


[35]

Bednarek N, Mathur A, Inder T, Wilkinson J, Neil J, Shimony J. Impact of therapeutic hypothermia on MRI diffusion changes in neonatal encephalopathy. Neurology. 2012 May 1:78(18):1420-7. doi: 10.1212/WNL.0b013e318253d589. Epub 2012 Apr 18     [PubMed PMID: 22517107]

Level 2 (mid-level) evidence

[36]

Gale C, Longford NT, Jeyakumaran D, Ougham K, Battersby C, Ojha S, Dorling J. Feeding during neonatal therapeutic hypothermia, assessed using routinely collected National Neonatal Research Database data: a retrospective, UK population-based cohort study. The Lancet. Child & adolescent health. 2021 Jun:5(6):408-416. doi: 10.1016/S2352-4642(21)00026-2. Epub 2021 Apr 21     [PubMed PMID: 33891879]

Level 2 (mid-level) evidence

[37]

Hu Y, Chen F, Xiang X, Wang F, Hua Z, Wei H. Early versus delayed enteral nutrition for neonatal hypoxic-ischemic encephalopathy undergoing therapeutic hypothermia: a randomized controlled trial. Italian journal of pediatrics. 2022 Aug 15:48(1):146. doi: 10.1186/s13052-022-01342-2. Epub 2022 Aug 15     [PubMed PMID: 35971138]

Level 1 (high-level) evidence

[38]

Mosalli R. Whole body cooling for infants with hypoxic-ischemic encephalopathy. Journal of clinical neonatology. 2012 Apr:1(2):101-6. doi: 10.4103/2249-4847.96777. Epub     [PubMed PMID: 24027701]